Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

Eitan Kerem, Michael W. Konstan*, Kris De Boeck, Frank J. Accurso, Isabelle Sermet-Gaudelus, Michael Wilschanski, J. Stuart Elborn, Paola Melotti, Inez Bronsveld, Isabelle Fajac, Anne Malfroot, Daniel B. Rosenbluth, Patricia A. Walker, Susanna A. McColley, Christiane Knoop, Serena Quattrucci, Ernst Rietschel, Pamela L. Zeitlin, Jay Barth, Gary L. ElfringEllen M. Welch, Arthur Branstrom, Robert J. Spiegel, Stuart W. Peltz, Temitayo Ajayi, Steven M. Rowe

*Corresponding author for this work

Research output: Contribution to journalArticle

209 Citations (Scopus)

Fingerprint Dive into the research topics of 'Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences